The global autoimmune disease diagnosis market size reached US$ 3.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028. The increasing incidences of autoimmune diseases, rising sales of insurance policies, and the growing use of EMRs represent some of the key factors driving the market.
An autoimmune disease is a group of disorders wherein the immune system attacks the cells, tissues, and organs of the body. It can be caused by different medical conditions, such as systemic lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes. It is associated with fatigue, joint pain and stiffness, skin rashes, fever, and digestive problems. It can also cause damage to organs and tissues, which leads to more severe symptoms like difficulty breathing, organ failure, or even death. It can be diagnosed via a combination of various approaches, such as taking a detailed medical history, performing a physical examination, blood tests to detect specific antibodies, imaging tests to look for damage or inflammation, and a biopsy to examine the affected tissue under a microscope.
Autoimmune Disease Diagnosis Market Trends:
The surging incidences of autoimmune diseases among individuals and the increasing aging population that are susceptible to develop such medical conditions represent one of the major factors driving the demand for autoimmune disease diagnosis around the world. Moreover, the rising awareness about autoimmune disease, its symptoms, diagnosis, and the easy availability of the treatment options is favoring the growth of the market. In addition, the growing implementation of health insurance policies that offer financial assistance for autoimmune disease diagnosis or treatment and reduce overall medical expenses is influencing the market positively. Apart from this, governing authorities of several countries are financing research and development (R&D) projects to study autoimmune diseases and develop new treatments. They are also investing in programs that aim to develop improved diagnostic methods for these medical disorders. Besides this, they are undertaking initiatives to offer quality healthcare facilities that are accessible to all. This, coupled with significant improvements in the diagnostic technologies, is strengthening the growth of the market. Furthermore, there is an increase in the use of electronic medical records (EMRs) to improve the accuracy and speed of autoimmune disease diagnosis as healthcare professionals have access to more comprehensive patient information. This, along with the rising adoption of telemedicine is catalyzing the demand for remote autoimmune disease diagnosis and monitoring technologies. Besides this, the growing demand for non invasive diagnosis, which is less painful as compared to traditional diagnostic procedures, is creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoimmune disease diagnosis market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, disease type, test type and end-user.
Product Type Insights:
- Consumables and Assay Kits
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the product type. This includes consumables and assay kits, and instruments. According to the report, consumables and assay kits represented the largest segment.
Disease Type Insights:
- Systemic Autoimmune Disease
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus (SLE)
- Multiple Sclerosis
- Localized Autoimmune Disease
- Inflammatory Bowel Disease
- Type 1 Diabetes
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the disease type has also been provided in the report. This includes systemic autoimmune disease (rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), multiple sclerosis, and others) and localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others). According to the report, localized autoimmune disease (inflammatory bowel disease, type 1 diabetes, thyroid, and others) accounted for the largest market share.
Test Type Insights:
- Routine Laboratory Tests
- Inflammatory Markers
- Autoantibodies and Immunologic Tests
The report has provided a detailed breakup and analysis of the autoimmune disease diagnosis market based on the test type. This includes routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. According to the report, routine laboratory tests represented the largest segment.
- Clinical Laboratories
A detailed breakup and analysis of the autoimmune disease diagnosis market based on the end-user has also been provided in the report. This includes clinical laboratories, hospitals, and others. According to the report, clinical laboratories accounted for the largest market share.
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for autoimmune disease diagnosis. Some of the factors driving the North America autoimmune disease diagnosis market included the easy availability of treatments, technological advancements, extensive research and development (R&D) projects, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global autoimmune disease diagnosis market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMérieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
|Base Year of the Analysis
||Product Type, Disease Type, Test Type, End-User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
|| Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMérieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., and Trinity Biotech plc
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the autoimmune disease diagnosis market from 2017-2028.
- The research study provides the latest information on the market drivers, challenges, and opportunities in the global autoimmune disease diagnosis market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the autoimmune disease diagnosis industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.